Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity

• Published in: International journal of biological sciences 2023-01, Vol.19 (14), p.4644-4656
• Main Authors: Sun, Xian, Wang, Wei-Jan, Lang, Jilu, Yang, Riyao, Shen, Wan-Jou, Sun, Linlin, Hsu, Jung-Mao, Chan, Li-Chuan, Li, Chia-Wei, Xia, Weiya, Ke, Baozhen, Yao, Guodong, Huang, Kebin, Lee, Pei-Chih, Koller, Paul B, Hung, Mien-Chie
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Anthracycline; Anthracyclines - pharmacology; Anthracyclines - therapeutic use; Antibiotics, Antineoplastic - therapeutic use; Antibodies; Antineoplastic Agents; Apoptosis; Breast cancer; Cancer; Cancer therapies; Cell death; Chemotherapy; Cytotoxicity; Doxorubicin; Doxorubicin - therapeutic use; Drugs; Flow cytometry; Galactosides; Galectin-9; Galectins; Humans; Immunomodulation; Immunosuppression; Immunosuppressive agents; Immunotherapy; Lymphocytes T; Mice; Neoplasms - drug therapy; Plasmids; Research Paper; RNA polymerase; Software; Tumor cell lines; Tumor Microenvironment; Tumors
• ISSN: 1449-2288; 1449-2288
• DOI: 10.7150/ijbs.84108

Anthracyclines are a class of conventionally and routinely used first-line chemotherapy drugs for cancer treatment. In addition to the direct cytotoxic effects, increasing evidence indicates that the efficacy of the drugs also depends on immunomodulatory effects with unknown mechanisms. Galectin-9 (Gal-9), a member of the β-galactoside-binding protein family, has been demonstrated to induce T-cell death and promote immunosuppression in the tumor microenvironment. Here, we asked whether anthracycline-mediated immunomodulatory activity might be related to Gal-9. We found that combining doxorubicin with anti-Gal-9 therapy significantly inhibited tumor growth and prolonged overall survival in immune-competent syngeneic mouse models. Moreover, Gal-9 expression was increased in response to doxorubicin in various human and murine cancer cell lines. Mechanistically, doxorubicin induced tumoral Gal-9 by activating the STING/interferon β pathway. Clinically, Gal-9 and p-STING levels were elevated in the tumor tissues of breast cancer patients treated with anthracyclines. Our study demonstrates Gal-9 upregulation in response to anthracyclines as a novel mechanism mediating immune escape and suggests targeting Gal-9 in combination with anthracyclines as a promising therapeutic strategy for cancer treatment.